Martigues

Malignant hypertension is a very serious form of high blood pressure that can be fatal if untreated. This research aims to create the first large, multicenter database to better understand this disease, including its modern epidemiology, how patients are currently managed, and the diseases diagnostic criteria. The study will help improve knowledge and may lead to new treatment trials and evidence-based recommendations. The study is an observational registry enrolling patients diagnosed with malignant hypertension based on classic definitions, including severe blood pressure elevation and organ damage. It plans to recruit 500 patients and follow them for five years to study their prognosis and the impact of different patient characteristics and organ involvement. By collecting detailed data on disease features and care pathways, the study hopes to update definitions and management approaches. Participants will be observed over five years, with researchers collecting information on their health status, organ damage, and treatment. The main outcome measured is the five-year prognosis of patients. This long-term follow-up will provide detailed knowledge about the disease course and help identify factors influencing outcomes, without any study treatments or interventions being assigned.

Hidradenitis Suppurativa HS is a skin condition that causes painful bumps, abscesses, scars, and tunnels in areas where the skin rubs together. This condition may start when hair follicles become damaged, triggering the immune system and allowing bacteria to worsen the symptoms. Researchers are evaluating the safety, effectiveness, and tolerance of a drug called zasocitinib in adults with moderate to severe HS compared with a placebo in this Phase 2 clinical trial. Participants will be randomly assigned to receive either zasocitinib or a placebo for the first 16 weeks in a double-blind period. After this, all participants will receive zasocitinib for an additional 36 weeks in an open-label period. The placebo capsules look like zasocitinib but contain no medicine. Treatment dosing involves a specific dose of zasocitinib labeled as Dose A. During the study, participants will visit the clinic 12 times for assessments. Researchers will monitor the percentage of participants achieving a 75% reduction in HS symptoms at week 16 as the primary outcome. They will also track safety through adverse events and other measures throughout the 56 weeks of treatment. Participants will undergo evaluations including clinical exams, questionnaires, and safety tests to understand treatment effects and tolerability.

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color due to the immune system mistakenly attacking pigment-producing skin cells called melanocytes. This leads to patches of skin with less or no pigment, often appearing symmetrically on both sides of the body in the nonsegmental form of vitiligo. The study aims to evaluate the safety, effectiveness, and tolerability of the drug zasocitinib in adults with nonsegmental vitiligo. Participants will receive oral capsules of zasocitinib at low, medium, or high doses for up to 52 weeks. Some participants will initially receive a placebo for 24 weeks, then switch to medium or high doses of zasocitinib for the remainder of the study. The placebo capsules look identical to zasocitinib but do not contain active medicine. The study uses a randomized, double-blind design with several experimental groups receiving different doses or placebo. During the study, participants will visit the clinic 11 times over one year. Researchers will assess the improvement in vitiligo using facial and total Vitiligo Area Scoring Index F-VASI and T-VASI at baseline and week 24. Safety and tolerability will also be monitored throughout. The primary outcome is the percentage of participants achieving at least 75% improvement in F-VASI at week 24. Secondary outcomes include other measures of vitiligo area improvement. Participants health and response to treatment will be closely followed until the studys end.

Researchers are evaluating the safety and effects of Abrocitinib in adults with moderate to severe atopic dermatitis, a long-lasting skin condition that causes inflammation, redness, and irritation. This observational study aims to understand how Abrocitinib works in real-life clinical settings for patients aged 18 and older who do not have other medical conditions that would prevent them from taking the medication. All participants will take Abrocitinib as a daily tablet and may also use medicated topical treatments for their condition. The study lasts 24 months, during which participants will be monitored regularly. They will visit the study clinic approximately five times, about once every 4 to 6 months, to report their experiences and health status while using the medication. Throughout the study, researchers will assess participants using various measures such as skin condition scores, itching severity scales, and sleep quality assessments. They will also track treatment adherence, any changes in medication dosage, and any side effects. The main outcome focuses on the proportion of patients achieving clear or almost clear skin after 16 weeks, with ongoing evaluations through 24 months to monitor safety and effectiveness.

Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.

This research aims to study people who have had their first episode of symptomatic deep vein thrombosis DVT in their lower limbs to understand the risk and severity of post-thrombotic syndrome PTS, the most common long-term complication of DVT. The study focuses on evaluating how the amount of thrombosis blood clot burden measured by the Venous Volumetric Index VVI on ultrasound relates to the development and severity of PTS assessed by the Villalta scale over 6 months. Participants will be followed at multiple times around 1 week, 1 month, 3 months, and 6 months after diagnosis. At each visit, doctors will assess symptoms and signs to calculate the Villalta score and perform venous ultrasounds to measure thrombosis burden using the VVI. Blood samples will be collected at several visits to study inflammation, coagulation, and clot breakdown factors. Quality of life questionnaires will also be completed at 3 and 6 months. During the study, symptom assessments, ultrasound exams, blood tests, and questionnaires will help researchers understand how the thrombosis burden at baseline and over time relates to the occurrence and severity of PTS. The study ends with the 6-month visit. Researchers will monitor the presence of moderate to severe PTS and changes in clot burden to identify important prognostic factors that may guide future prevention and treatment strategies.

Psoriasis is a chronic inflammatory condition influenced by genetic and environmental factors, often leading to recurrent skin flare-ups. This trial evaluates the effectiveness of bimekizumab, a drug, compared to topical corticosteroids in managing psoriasis symptoms. The study aims to determine if early intervention with bimekizumab can delay the chronic inflammation typically seen in psoriasis over a 24-week period. Participants will be randomly assigned to one of two groups one group receives 320mg of bimekizumab at weeks 0, 4, 8, and 12, while the other uses clobetasol ointment daily for up to 4 weeks until the lesion clears. Afterward, clobetasol will be applied twice weekly until week 16, then stopped. No active treatment is given between weeks 16 and 24. From week 24 to 96, patients who experience flare-ups may use clobetasol continuously but will be classified as non-responders for main analysis. If psoriasis worsens to moderate or severe, participants leave the study for standard care. During the study, various assessments and sample collections will monitor the disease and treatment effects. Researchers will measure psoriasis activity using clinical tools at 24 weeks, focusing on skin condition and quality of life. Patients must attend all study visits and follow procedures, with the total participation period extending to up to 96 weeks depending on flare-ups and treatment response.

Benign prostatic hyperplasia BPH, also known as prostate adenoma, is a common non-cancerous enlargement of the prostate affecting mainly men over 40 years old. This condition often causes lower urinary tract symptoms LUTS such as difficulty starting urination, frequent urination, especially at night, and a decrease in urine flow. Researchers are evaluating the safety and effectiveness of a high-intensity focused ultrasound HIFU treatment specifically targeted to reduce prostate volume and improve urinary symptoms in men with BPH. The study uses HIFU, a technique that applies focused ultrasonic waves to heat and destroy targeted prostate tissue precisely without invasive surgery or radiation. This treatment is delivered endorectally using a specialized probe to target the affected prostate areas. The study observes patients at 3, 6, 12, 18, and 36 months after treatment to assess safety, symptom improvement, prostate size reduction, urinary flow changes, and sexual function. Participants will undergo various assessments including MRI scans, urinary flow measurements, and questionnaires on urinary symptoms, quality of life, and erectile and ejaculatory function. Researchers will monitor adverse events and treatment effects over 36 months. The study aims to gather detailed information about treatment safety and effectiveness through regular follow-up visits and evaluations.

This research aims to evaluate patient satisfaction after a multidisciplinary complex assessment conducted in a Day Hospital for adults diagnosed with cancer and scheduled to receive injectable anticancer treatment. The study focuses on understanding how patients feel about this coordinated care approach involving multiple healthcare professionals and its impact on overall quality of care in oncology. The assessment involves consultations with a pharmacist, dietitian, psychologist, social worker, and supportive care providers to identify patient-specific needs and improve care coordination early in the treatment process. All patients undergoing this assessment are invited to complete an anonymous satisfaction questionnaire as part of routine care. Participants will complete the satisfaction questionnaire after their Day Hospital assessment, covering quality of care, interactions with healthcare providers, and organization of services. Researchers will analyze overall satisfaction, satisfaction by specialty, factors influencing satisfaction, and the Net Promoter Score. Results aim to enhance patient-centered oncology care and guide continuous quality improvement until the study ends in April 2029.

Researchers are evaluating whether a new imaging method called high resolution micro-ultrasound microUS, approved by the FDA and Health Canada, is as effective as the current standard imaging technique, multiparametric MRI, for screening the prostate gland. This phase 3 clinical trial aims to identify which imaging approach better guides the decision to proceed with a prostate biopsy in men aged 50 to 70 who are at risk for prostate cancer. Participants will be randomly assigned to one of two groups to receive either the standard prostate multiparametric MRI or the experimental microUS imaging. These imaging procedures will be compared to assess their ability to detect prostate abnormalities. The study is conducted at multiple centers internationally, and both imaging methods are non-invasive diagnostic devices. Men enrolled in the study will be followed for one year after their imaging test to monitor the detection of clinically significant prostate cancer. Researchers will collect data on imaging results and biopsy decisions to evaluate each methods effectiveness. Participants will undergo standard clinical assessments, and study visits will be scheduled to track outcomes during the follow-up period.